Companies › Polarean
1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 3; Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Albuterol Sulfate Beta-2 adrenergic receptor agonist | ADRB2 | Phase 1 | Chronic Obstructive Pulmonary Disease; Bronchiolitis | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06271408 | Albuterol Sulfate | Phase 1 | Chronic Obstructive Pulmonary Disease | Respiratory | Dec 2026 |
| NCT06946264 | Albuterol Sulfate | Phase 3 | Bronchiolitis | Respiratory | Dec 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.